2022
Real-world evaluation of safety and effectiveness of dydrogesterone in the management of threatened abortion
Nagarkatti R, Mehra D, Mandal S, Dhawan A, Joshi P, Nagarkatti N, Chinda M, Jaiswal A. Real-world evaluation of safety and effectiveness of dydrogesterone in the management of threatened abortion. International Journal Of Reproduction Contraception Obstetrics And Gynecology 2022, 0: 2096. DOI: 10.18203/2320-1770.ijrcog20221833.Peer-Reviewed Original ResearchLow back painOral dydrogesteroneBack painPregnancy lossRetrospective analysisReal-world retrospective analysisMain presenting symptomRelief of symptomsWeeks of gestationCase report formsTreatment of womenVaginal bleeding/Establishment of hemostasisDydrogesterone treatmentAbdominal painPresenting symptomTolerability profileAdverse eventsCommon complicationMedian timeEndogenous progesteroneFirst trimesterSurgical interventionBleeding/Case report
2021
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Roque D, Bellone S, Siegel E, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz P, Ratner E, Alexandrov L, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Journal Of Clinical Oncology 2021, 39: 5523-5523. DOI: 10.1200/jco.2021.39.15_suppl.5523.Peer-Reviewed Original ResearchObjective response rateImmune checkpoint inhibitorsEndometrial cancer patientsTumor mutational burdenCancer patientsGrade 3/4 treatment-related adverse eventsSolid Tumors version 1.1Treatment-related adverse eventsSporadic tumorsPhase II pilot studyOverall survival proportionPrimary end pointResponse Evaluation CriteriaPhase II evaluationAntigen processing/presentationProcessing/presentationAdverse eventsICI resistancePrognostic significanceMechanisms of resistancePolymerase chain reactionII evaluationClinical studiesMutational burdenPatients